1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Abbott and Solvay set swap ratio for Indian merger

 
• By Anju Ghangurde

Abbott India gained sharply on Indian bourses after the company announced plans to amalgamate the operations of Solvay Pharma India with itself.

Abbott India gained sharply on Indian bourses after the company announced plans to amalgamate the operations of Solvay Pharma India with itself.

Shares of Abbott India rose by 3.3% to touch Rs1,472.75 ($32.40) on 24 November after the company said that its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?